Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure

BACKGROUND. Mitoxantrone was approved for use in metastatic castrate-resistant prostate cancer (mCRPC) based on pain palliation without observed survival benefit in a small phase III trial in 1996. To re-evaluate for possible survival benefits in a larger contemporary sample and to demonstrate analy...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Green, Angela K., Corty, Robert W., Wood, William A., Meeneghan, Mathew, Reeder-Hayes, Katherine E., Basch, Ethan, Milowsky, Matthew I., Dusetzina, Stacie B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2015
Konular:
Genitourinary Cancer
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425389/
https://ncbi.nlm.nih.gov/pubmed/25888270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0432
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller